Menopause

Pvolve Expands Leadership Team Following Year of Exponential Growth

Fast-scaling fitness company hires Stacey Heald as new Chief Operating Officer of Franchise Development and Alexis McDowel as first global…

10 months ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…

10 months ago

Bone Health Technologies Announces FDA Clearance of OsteoboostTM, the First Prescription Medical Device to Treat Low Bone Density

Osteoboost is the first and only non-pharmacological prescription treatment to demonstrate reduced loss of bone strength in postmenopausal womenRepresents the…

10 months ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newbornsSAN…

10 months ago

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and…

11 months ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

$5 million at closing and up to $7 million of additional committed fundingSAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) --…

11 months ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary DysmenorrheaSAN DIEGO, Dec. 20,…

11 months ago

Women’s Health Associates Selects AI-powered, Ambient Listening Technology Sunoh.ai to Transform Clinical Documentation and Improve Quality Care

The women’s health practice aims to streamline documentation, provide personalized attention to its patients, and drive efficiencies by leveraging the…

12 months ago

Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE)…

12 months ago

Biodentical Hormone Therapy Awareness Advanced By Suzanne Somers, Says Dr. Paul Savage

Dr. Savage, CEO of MDLifespan in Chicago, says that by sharing her personal story she advanced awareness of Biodentical Hormone…

1 year ago